Paraneoplastic Phenomena and Diagnostic Challenges in Angioimmunoblastic T-Cell Lymphoma (AITL): Report of Two Cases and Review of the Literature.

Pircher, A; Verdorfer, I; Brunner, A; Hopfinger, G; Steurer, M; In Vivo. 2014; 28(3): 327-332.

Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells.

Hofbauer, SW; Krenn, PW; Ganghammer, S; Asslaber, D; Pichler, U; Oberascher, K; Henschler, R; Wallner, M; Kerschbaum, H; Greil, R; Hartmann, TN; Blood. 2014; 123(14):2181-2188

Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin“s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy.

Fridrik, MA; Greil, R; Hausmaninger, H; Krieger, O; Oppitz, P; Stöger, M; Klocker, J; Neubauer, M; Helm, W; Pont, J; Fazeny, B; Hudec, M; Simonitsch, I; Radaszkiewicz, T; Ann Hematol. 2014; 93(3): 539-540.

Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer–a phase II clinical trial.

Eisterer, W; De Vries, A; Öfner, D; Rabl, H; Koplmüller, R; Greil, R; Tschmelitsch, J; Schmid, R; Kapp, K; Lukas, P; Sedlmayer, F; Höfler, G; Gnant, M; Thaler, J; Anticancer Res. 2014; 34(11):676-673

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.

Te Raa, GD; Malčiková, J; Mraz, M; Trbusek, M; Le Garff-Tavernier, M; Merle-Béral, H; Greil, R; Merkel, O; Pospíšilová, S; Lin, K; Pettitt, AR; Stankovic, T; van Oers, MH; Eldering, E; Stilgenbauer, S; Zenz, T; Kater, AP; Br J Haematol. 2014; 167(4): 565-569.

Quality of care of rural rheumatoid arthritis patients in Austria.

Puchner, R; Brezinschek, HP; Herold, M; Nothnagl, T; Studnicka-Benke, A; Fritz, J; Leeb, BF; Wien Klin Wochenschr. 2014; 126(11-12): 360-367.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb, J; Tabernero, J; Mini, E; Subtil, F; Folprecht, G; Van Laethem, JL; Thaler, J; Bridgewater, J; Petersen, LN; Blons, H; Collette, L; Van Cutsem, E; Rougier, P; Salazar, R; Bedenne, L; Emile, JF; Laurent-Puig, P; Lepage, C; Lancet Oncol. 2014; 15(8): 862-873.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan, FT; Hillmen, P; Hellmann, A; Robak, T; Hughes, SG; Trone, D; Shannon, M; Flinn, IW; Byrd, JC; Br J Haematol. 2014; 167(4): 466-477.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts, C; Socinski, MA; Mitchell, PL; Thatcher, N; Havel, L; Krzakowski, M; Nawrocki, S; Ciuleanu, TE; Bosquée, L; Trigo, JM; Spira, A; Tremblay, L; Nyman, J; Ramlau, R; Wickart-Johansson, G; Ellis, P; Gladkov, O; Pereira, JR; Eberhardt, WE; Helwig, C; Schröder, A; Shepherd, FA; Lancet Oncol. 2014; 15(1): 59-68.

αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Berghoff, AS; Kovanda, AK; Melchardt, T; Bartsch, R; Hainfellner, JA; Sipos, B; Schittenhelm, J; Zielinski, CC; Widhalm, G; Dieckmann, K; Weller, M; Goodman, SL; Birner, P; Preusser, M; Clin Exp Metastasis. 2014; 31(7):841-851